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EDITORIAL REVIEW
Rhabdomyolysis and myohemoglobinuric acute renal failure
Muscle accounts for approximately 40% of total body mass and
falls victim to a wide variety of toxic, ischemic, infectious, inflam-
matoiy, and metabolic insults. The final result of these diverse
assaults may be muscle fiber dissolution, or rhabdomyolysis,
resulting in the release of potentially toxic intracellular compo-
nents into the systemic circulation. The rhabdomyolysis syndrome
has been recognized for centuries. Indeed, the Bible alludes to its
occurrence [1]. However, it was not until Bywaters' and Beall's
classic description of the "crush syndrome," a result of the
bombing raids of London during World War II, that the renal
complications of rhabdomyolysis became firmly entrenched in the
medical literature [2]. Since then, a plethora of non-traumatic
causes of muscle necrosis have been recognized, and today
rhabdomyolysis is considered a leading cause of acute renal
failure (ARF). For example, at Harborview Medical Center, a
Seattle municipal hospital, it accounts for approximately 10 to
15% of all ARF cases. In recent years, a number of important
pathophysiologic insights into the nature of rhabdomyolysis-
induced ARF have emerged, offering potentially new prophylactic
and therapeutic approaches. Therefore, this article has the fol-
lowing goals: (1) review the pathophysiology of myonecrosis, in
general, and some of its specific causes; (2) discuss how muscle
necrosis can negatively impact the kidney, potentially culminating
in tubular necrosis and ARF; and (3) using this pathophysiologic
information as a backdrop, review current and possible future
pharmacologic approaches for the management of this dramatic
and often life threatening "myo-renal syndrome."
Muscle structure, function, and the development of
rhabdomyolysis
Muscles are comprised of innumerable elongated multinucle-
ated cells (myocytes), created during embryogenesis by cell fusion.
Each cell forms a fiber which is enclosed within endomysial
connective tissue. Bundles of adjacent fibers are surrounded by
perimysial connective tissue, forming muscle fascicles. The fasci-
des are separated from each by the epimysium, a dense connec-
tive tissue which contains the organ's vascular and neuronal
elements. The functional "motor unit" is comprised of the
anterior horn cell within the spinal cord, its axon, and the muscle
fibers it supplies [3]. While fibers within a given motor unit are
scattered throughout the muscle (that is, a "mosaic" pattern of
distribution), each of the fibers within a given unit are metaboli-
cally similar, being of one of two types. "Slow," or type 1, fibers
are characterized by oxidative metabolism, and hence, they have
abundant mitochondria and a high myoglobin content. The latter
comprises - 2% of total muscle weight and functions to store
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oxygen for mitochondrial consumption during periods of in-
creased oxidative metabolism. In contrast, "fast," or type 2, fibers
are predominantly glycolytic; hence, they have relatively few
mitochondria and little myoglobin content (that is, "white" as
opposed to "red" muscle). Given these distinctly different meta-
bolic profiles, it is not surprising that "slow fibers" are utilized for
prolonged, sustained muscular activity (for example, maintenance
of posture or continuous athletic activity). Conversely, "fast
fibers" undertake sudden, forceful contractions [3—5].
The myocyte plasma membrane, or sarcolemma, maintains a
transcellular electrical potential gradient of approximately —90
mV, largely a result of Na,K-ATPase activity. In response to a
neuronal impulse, the nerve endings release acetylcholine which
opens acetylcholine-gated sarcolemmal sodium channels. Depo-
larization and an action potential result. As the depolarization
wave traverses the muscle fiber, Ca2 is released from the
endoplasmic (or sarcoplasmic) reticulum. The released (free)
Ca2 reverses troponin-tropomyosin inhibition of actin-myosin
binding, ATP is cleaved by myosin-associated ATPase and
contraction results. Relaxation is effected as Ca2 is actively
transported back into the sarcoplasmic reticulum via an ATP
dependent process, permitting re-establishment of the troponin-
tropomyosin inhibition of actin-myosin binding. Finally, ATP is
required for restitution of the resting sarcolemmal electrical
potential via Na,K-ATPase activity. From these brief consider-
ations, it is clear that ATP is critical to muscle contraction,
relaxation, and maintenance of baseline myocyte homeostasis
[3—51.
As will be discussed below, most forms of muscle necrosis are
triggered by derangements in oxidative or glycolytic energy pro-
duction and the resulting ATP depletion. The latter causes
profound disturbances in myoeyte ion homeostasis with cytosolic
Ca2 overload being a result. The latter is widely purported to be
the critical trigger initiating myocyte dissolution [3]. Several
potential and overlapping mechanisms lead to myocyte Ca2
overload, some of which are briefly discussed: First, direct sar-
colemmal damage, such as from physical/exertional trauma or
toxic injury, can permit direct Ca2 influx across the sarcoplasmic
membrane [31, as dictated by a steep extracellular-intracellular
concentration gradient (—10,000:1). Second, in the presence of
concomitant ATP depletion, a failure of Ca2 ATPase-driven
Ca2 efflux results, permitting a sustained increase in myocyte
free Ca2 content. Third, ATP depletion interferes with normal
intracellular Ca2 sequestration within the sarcoplasmic reticu-
lum and the mitochondria. Fourth, with progressive mitochondrial
and sarcoplasmic damage, Ca2 which is normally stored within
these organelles can be released, further contributing to the Ca2
overload state. Fifth, Na influx down its transmembrane gradient
stimulates Nat1Ca2+ exchange, which further depletes the resid-
ual ATP pool, while at the same time contributes to the intracel-
lular Ca2 burden. Thus, a failure of Ca2 sequestration, in-
creased influx, and decreased efflux synergistically produce lethal
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Table 1. Causes of rhabdomyolysis
Direct muscle injury
Crush syndrome, including pressure (coma-induced) necrosis











Sepsis syndrome (bacterial, viral; hyperthermia)
Inflammatory myopathies (polymyositis; infectious myopathies)
Hereditary disorders [44]
Glycogenolytic enzyme deficiencies
(such as McArdle's syndrome)
Defective lipid metabolism
(such as carnitine palmitoyltransferase/carnitine deficiency)
Miscellaneous
(such as malignant hyperthermia/neuroleptic malignant syndrome)
Drugs
for example, alcohol, cocaine, amphetamine, opiates, neuroleptics,
clofibrate, lovastatin
Toxins
for example, Tetanus, typhoid, staphyloccal, snake/insect toxins
Ca2 overload. Once a critical free Ca2 concentration develops,
neutral proteases (such as calpain), phospholipases (such as
PLA2), and presumably other degradative enzymes are activated,
resulting in myofibril and membrane phospholipid damage, re-
spectively [3]. Selected byproducts of these reactions, most nota-
bly fatty acids and lysophospholipids, can potentiate the resulting
injury by altering ionic transport or via direct membrane lytic
effects. Furthermore, Ca2 damaged mitochondria may generate
large amounts of superoxide in the ubiquinone region of the
respiratory chain; thus, superimposed oxidant stress develops [6].
The net result of these multiple, overlapping, and often self
sustaining processes is myocyte lysis with release of toxic intracel-
lular constituents into the extracellular microenvironment. Local
accumulation of these products may cause microvasculature dam-
age, producing capillary leak and rising intracompartmental pres-
sures [6, 7]. Neutrophil adherence to damaged endothelial cells
can further compromise tissue perfusion [7—13], thereby potenti-
ating tissue ischemia and the evolving muscle damage. With this
as a background, some relatively common or illustrative condi-
tions which can trigger this injury cascade will be presented. A
more exhaustive list of potential causes of rhabdomyolysis appears
in Table 1.
Muscle injuries which can culminate in rhabdomyolysis
Crush syndrome
Crush injuries sustained during the Battle of Britain formed the
basis for Bywaters' and Beall's classic descriptions of rhabdomy-
olysis-associated ARE [2]. While this form of injury is now seen
most often as a sporadic event, it can still occur in "epidemic"
proportions, as tragically demonstrated by U.S. Marines bombing
of Beirut barracks in 1983 [141,and by the Armenian earthquake
of 1988 in which 600 patients developed myoglobinuric ARF [15].
The pathophysiology of crush syndrome-induced muscle injury,
while seemingly straightforward, is actually quite complex. The
earliest insult may be "pressure-stress myopathy" in which exter-
nal pressure/tension on muscle causes increased sarcolemmal
Na and Ca2 influx down their concentration gradients [16—18].
External pressure-induced occlusion of the microcirculation also
occurs, rapidly depleting ambient and myoglobin oxygen content.
While some high energy phosphate reserves exist in the form of
creatine phosphate, these stores are soon depleted, glycogen
stores are exhausted, and severe ATP depletion ensues. Despite
this onerous situation, cell viability may remain intact for consid-
erable periods of time, for a number of reasons [19]: (1) pressure-
induced vascular occlusion limits Ca2 delivery to ischemic tis-
sues; hence, this may stave off critical muscle Ca2 loading,
forestalling the onset of cell necrosis. (2) Mitochondrial oxygen
free radical production is markedly reduced during ischemia
because oxygen deprivation stops electron transport; thus, de-
creased rather than increased mitochondrial H202 and superox-
ide production may result [20]. (3) Intracellular/extracellular
acidosis, a correlate of tissue ischemia, has a remarkably potent,
and apparently generalized cytoprotective effect [21—241. With
restitution of blood flow, each of these intrinsic homeostatic
mechanisms are reversed: Ca2 influx occurs, brisk mitochondrial
oxygen free radical formation may result, and tissue acidosis
recedes. Furthermore, restoration of blood flow allows for neu-
trophil influx, which can re-occlude the microcirculation and
release proteases and free radicals into the microenvironment.
Hence, a new wave of injury results [19]. These considerations
indicate that although the crush lesion clearly sets the stage for
rhabdomyolysis, many of its critical components are enacted
during the reperfusion period. It is also during the latter time that
myoglobin gains ready access to the circulation, and extracellular
fluid depletion results because of muscle/soft tissue fluid seques-
tration. These two factors are critical to the evolution of crush
syndrome-induced ARE, as will be discussed at length later in this
review.
Exertional rhabdomyolysis
Strenuous physical exercise is probably the most common cause
of severe rhabdomyolysis, particularly when it is performed by
untrained individuals in hot, humid weather. Therefore, it is not
surprising that outbreaks of myonecrosis have been noted at
Southern military bases and summer sports training camps [25,
26]. However, non-athletic exertion can also produce this result,
as evidenced by the onset of myoglobinuria following generalized
convulsions or septic rigors [27]. The specific events leading to
exertional myonecrosis have only been partially clarified, and the
syndrome develops in stages [28]: The initiating stage is believed to
result from mechanical muscle fiber injury, induced, in particular,
by eccentric contractions and when the muscle is in an elongated
condition (such as down hill walking [28—30]). These factors
produce excessive tensile stress and heat generation, resulting in
muscle fiber injury. Continuous contractions can also compromise
muscle capillary blood flow. When coupled with progressive
glycogen and creatirie high energy phosphate consumption, ATP
depletion results. The Ca2 overload stage is thought to be
initiated by a Ca2 influx across a mechanically damaged myocyte
sarcolemmal membrane [28—3 1]. For reasons noted above, con-
comitant energy depletion either initiates or markedly contributes
to this result. Ca2 overload is then believed to initiate the
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autogenous phase, during which phospholipase and protcase acti-
vation, mitochondrial dysfunction, and free radical formation
perpetrate sarcalemmal injury, culminating in cell death [28, 32].
Muscle hyperthermia (as much as 43°C), induced by strenuous
exercise in concert with impaired heat dissipation (by hot humid
conditions), undoubtedly plays a major role in these processes
[33], for at least two reasons. First, a rising muscle temperature
markedly increases metabolic rate, and hence, ATP consumption.
While this may be well tolerated by otherwise normal tissues, it
can cause profound ATP depletion in cells with already compro-
mised glycolytic or mitochondrial energy production [34]. Second,
enzymatic degradative reactions are highly thermal dependent,
generally increasing by —10% for each 1°C increment. This not
only accelerates tissue injury, but it can also convert sublethal into
lethal cell damage [35].
Of considerable interest is the mechanism by which prior
muscle conditioning prevents the above sequence of events [26,
33]. It presumably reflects a cellular adaptation to prior exercise-
induced sublethal injury. The exact pathways by which it is
effected remain to be defined. However, it is noteworthy that
sublethal injury-induced "cellular conditioning" may not neces-
sarily be confined to skeletal muscle. For example, the post-
ischemic myocardium can acutely develop partial resistance to
further ischemic injury (the "stunning phenomenon" [36]), and
during the early recovery phase of ARF, tubules demonstrate
heightened resistance to further toxic or ischemic insults [37—40].
Whether these phenomena reflect common adaptive mechanisms
remains unknown.
Intrinsic myopathies
The first report of a presumptive metabolic disorder causing
recurrent myonecrosis appeared in 1884 [41]. Approximately 30
minutes after the onset of strenuous exercise, horses were noted
to develop muscle tremors, weakness, and limpness, followed by
myoglobinuria. In 1910, a similar disorder was noted in a 13-year-
old boy [42]. However, it was not until the detailed reports of
McArdle in 1951 that the study of hereditary disorders which
trigger rhabdomyolysis began in earnest [43]. Since that time, a
panoply of muscle energy production disturbances have been
documented, of which McArdle's disease is a prototype. Excellent
reviews of this area are available [3, 44], and a detailed description
of this subject is beyond the scope of this review. However, two
general issues are worth noting. First, these disorders typically
present as recurrent episodes of muscle pain with or without overt
myoglobinuria. Clues to an underlying metabolic disorder include:
(a) onset in childhood; (b) a positive family history; (c) mild
baseline creatine phosphokinase elevations; (d) onset of clinically
overt muscle necrosis with either mild exercise or no obvious
precipitating event; and (e) recurrent attacks. Second, divergent
defects can give rise to this pathology, including deranged glyco-
lysis, altered mitochondrial function, and impaired muscle excita-
tion.
McArdle's disease. McArdle's disease is the most common cause
of the first set of disorders and is believed to be due to myophos-
phorylase deficiency. Since this enzyme promotes glycogenolysis,
its deficiency presumably causes defective anaerobic energy pro-
duction in type II fibers, culminating in exercise-induced ATP
depletion and myonecrosis.
Carnitine palmitoyl transferase deficiency. This is the prototypic
mitochondrial disorder giving rise to recurrent rhabdomyolysis.
This enzyme is required for transport of long chain fatty acids
across the inner mitochondrial membrane; hence, its deficiency
leads to defective mitochondrial energetics, and presumably ex-
ercise-induced ATP depletion.
Malignant hyperthermia. The third general category of genetic
muscle disorders leading to rhabdomyolysis is represented by
malignant hyperthermia. Classically, it presents with the onset of
muscle rigidity and contractures, a rapidly rising body tempera-
ture (as much as 1°C every s mm; reaching  43°C), and
myonecrosis. Although the exact genetic and metabolic basis for
this disorder remain unknown, it is believed to be due to altered
excitation-contraction coupling, resulting in increased sarcolem-
mal Ca2 transport, contractures, and increased muscle heat
production. That attacks are often (but not invariably) triggered
by halogenated hydrocarbon anesthetic and succinylcholine expo-
sure are clues to the diagnosis. Specific diagnostic and therapeutic
approaches to these hereditary disorders have recently been
reviewed by Brumback, Feeback and Leech [3].
Alcoholism, hypophosphatemia, and hypokalemia
Alcoholism is a leading cause of rhabdomyolysis [27] and may
contribute to muscle injury in a variety of ways. For example, it
can predispose to or cause trauma, seizures, or coma-induced
("found down") ischemic pressure necrosis. It is also a direct
muscle toxin, inducing either chronic or acute myopathy. Knochel
has performed much of the pioneering work in this area and
readers are referred to several of his excellent reviews of this
subject [33, 45—47]. In brief, alcohol intake, independent of
concomitant malnutrition, induces substantial changes in muscle
ion homeostasis, including increments in Na, C1, and Ca2, and
decrements in Mg2, K, and phosphate content. These changes
are associated with increased Na,K-ATPase activity, suggesting
that ethanol directly injures the sarcolemma, allowing for in-
creased Na entry [33, 48]. A secondary increase in Ca2 may
then result via enhanced Na7Ca2 exchange. Given calcium's
critical role in mediating rhabdomyolysis, these processes may
either initiate myonecrosis, or predispose the muscle to concom-
itant insults, such as electrolyte disturbances, as discussed below.
Hypophosphatemia is a frequent co-existent risk factor for
alcohol-induced rhabdomyolysis [33, 45, 46], although the direct
mechanisms by which it does so have remained somewhat elusive.
A leading possibility is that intracellular inorganic phosphate
deficiency limits ATP production, potentially imposing an energy
deficient state. The latter would then predispose to intracellular
Ca2 loading, ultimately triggering myocyte death. While chronic
phosphate depletion can induce myopathy [49], it rarely produces
overt rhabdomyolysis in the absence of alcohol intake. Hence, it is
postulated that phosphate depletion only initiates myonecrosis in
the presence of pre-existent muscle damage [33, 50]. This is
particularly likely to occur during a period of caloric, but phos-
phate deficient, refeeding (such as, glucose infusion). A possible
reason for this is that cellular glucose uptake obligates phosphate
utilization (glucose 6 phosphate formation), potentially triggering
severe intracellular inorganic phosphate- and ATP-depletion.
With the onset of muscle necrosis, intracellular phosphate is
released. This may rapidly correct the hypophosphatemia, thereby
obscuring its original pathogenetic contribution to the muscle
injury.
Hypokalemia is the second electrolyte disturbance which may




initiate or contribute to rhabdomyolysis-induced ARF Com-
mon underlying causes include physical exercise in hot weather
(sweat and urinary K losses), long-acting diuretic therapy, and
alcoholism. As with acute hypophosphatemic myopathy, it may be
difficult to document hypokalemia with the onset of myonecrosis
because of the resulting cellular K loss. Two mechanisms for
hypokalemic rhabdomyolysis have been suggested, both of which
relate to altered myocyte energetics. First, K depletion can
interfere with glycogen synthesis [5fl. Second, the exercising
muscle may fail to develop reactive hyperemia, a prerequisite for
increased oxygen delivery during a period of increased oxygen
demand [52]. Since this vasodilatory response is dependent on
myocyte K release and the attainment of high muscle interstitial
K concentrations (—10 to 15 mEq/liter), a pre-existent K
deficiency may prevent this critical adaptive response. Thus, a
combination of diminished glycogen reserves and impaired oxy-
gen delivery/aerobic energy production may induce energy deple-
tion which then initiates myocyte death.
Mechanisms of myohemoglobinuric renal injury
The association of rhabdomyolysis with ARF was well estab-
lished at the time of World War I. However, that myoglobin was
directly involved in the induction of the renal damage was not
definitively established until Bywaters and Stead induced ARF by
myoglobin infusion [53, 54]. Those experimental studies also
revealed the two critical factors which predispose to myohemo-
globinuric ARF: hypovolemia/dehydration and aciduria. Indeed,
it has been repeatedly demonstrated that in their absence, heme
proteins have minimal nephrotoxic effects. At the nephronal level,
three basic mechanisms underlie heme protein toxicity: renal
vasoconstriction, intraluminal east fonnation, and direct heme pro-
tein-induced cytotoxicby [55]. The following discussion will address
each of these factors and stress the nature of their critical
interactions, as depicted in Figure 1. In this discussion, the renal
effects of hemoglobin and myoglobin are considered together
(that is, "heme proteins") since they are thought to have the same
renal impact.
Fig. 1. Potential pathways underlying
rhabdornyolysis-induced renal injury. Renal
hypoperfusion/ischemia, iron mediated proximal
tubule eytotoxicity, and cast formation are
postulated to play central, hut interrelated,
mechanisms which lead to proximal tubular
necrosis and ARF. Filtration failure ultimately
results from some combination of proximal
tubular necrosis, tubular obstruction, and a
renal vasoconstricted state.
Renal vasoconstriction
The two most widely used experimental models of heme
protein-induced ARF are either heme protein (hemoglobin/
myoglobin) infusion into dehydrated/volume depleted animals or
intramuscular hypertonic glycerol injection. The latter causes
myolysis, hemolysis, and intravascular volume depletion. The
importance of the latter and its associated renal vasoconstriction
are underscored by the fact that either volume expansion or early
renal vasodilator therapy can prevent, or profoundly attenuate,
heme protein-induced ARF [56]. That intravascular volume de-
pletion is a near constant correlate of clinical rhabdomyolysis [14,
16, 19], and that hemoglobinuria rarely induces ARF in volume
expanded individuals [57], indicate the relevance of these exper-
imental observations.
Several potential mechanisms may contribute to renal vasocon-
striction/hypo-perfusion in the setting of rhabdomyolysis: First,
muscle necrosis causes dramatic fluid third spacing, leading to
intravascular volume depletion. Better indicated that following
severe crush injuries, as much as 18 liters of fluid may extravascate
into damaged limbs [14]. That aggressive volume repletion (—1
liter/hr) during the early post-injury period can dramatically
decrease the incidence of clinical rhabdomyolysis-induced ARF
[14, 58, 59] underscores the pathogenetic importance of this
volume depleted/renal vasoconstricted state. Second, severe mus-
cle injury can, for unceretain reasons, activate the endotoxin
cytokine cascade. Its pathogenetic role in rhabdomyolysis-induced
ARF has been convincingly demonstrated by several studies by
demonstrating that either active or passive endotoxin tolerance
prevents heme protein-induced renal damage [60—621. Since
endotoxemia elicits renal vasoconstriction [63, 64] and can de-
press left ventricular function [651, it is quite plausible that
endotoxin's adverse effects are mediated by an increase in rhab-
domyolysis-associated renal vasoconstriction. That endotoxin tol-
erance abrogates renal vasoconstriction and filtration failure in a
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[64]. Third, heme proteins scavenge nitric oxide (NO), an impor-
tant endogenous vasodilator [66—681. Studies by Brezis et a! have
demonstrated NO's importance in maintaining renal medullary
oxygenation, an area with a tenuous blood supply [691. That
interventions which increase and decrease NO protect against and
exacerbate various forms of experimental ARF, respectively,
underscore the potential importance of NO in the expression or
toxic and ischemic tubular damage [70—76]. Finally, Wright, Rees
and Moncada have indicated that NO synthase inhibition in
experimental septic shock markedly increases vasoconstriction,
producing worse end organ tissue damage and rapid death [77].
Hence, it seems clear that heme protein-induced NO scavenging
could directly contribute to renal hypoperfusion and tissue injury
in the setting of rhabdomyolysis. Recent demonstrations that NO
synthase inhibition worsens, and NO supplementation protects
against the glycerol ARF model, respectively, directly support this
view [78].
A recent elegant study by Vetterlein et at has provided com-
pelling evidence that myoglobinemia exacerbates renal hypoper-
fusion in the setting of acute volume depletion [79]. These
workers infused myoglobin into normal rats or rats which had
been subjected to acute hemorrhagic shock (50 mm Hg). Total
renal blood flow was measured by electromagnetic flow probe,
and cortical and medullary microperfusion were assessed by a
fluorescent dye technique. Whereas myoglobin infusion had no
discernible effect on renal perfusion in normal animals, it pro-
foundly exacerbated cortical and medullary hypoperfusion in the
hypotensive animals. The potential impact of this change on tissue
energetics and cell injury had previously been addressed by a
study from our laboratory [801. Employing a similar protocol to
that used by Vetterlein, we noted that myoglobin infusion caused
profound reductions in renal cortical ATP concentrations in
hypotensive rats. This resulted in a marked exacerbation of tissue
injury, resulting in anuric ARF. In data gathered during, but not
reported in that study, myoglobin infusion also exacerbated
shock-induced hepatic ATP depletion. Clearly, then heme pro-
teinemia can have a profoundly negative impact on cellular
energetics and shock-induced tissue injury. It is noteworthy that
these adverse effects may be clinically masked by heme's ability to
maintain mean arterial pressure (MAP) during acute volume
depletion states [80—82], presumably by NO scavenging. This
suggests that although heme proteins may help to maintain MAP
via an increase in peripheral vascular resistance, ischemic tissue
injury may still result.
The above studies strongly suggest that renal vasoconstriction
participates in the expression of heme protein-associated ARF via
the induction of renal tubular ATP depletion (discussed in greater
detail below). However, renal vasoconstriction can also facilitate
heme toxicity by increasing cast formation and by promoting
proximal tubular cell heme uptake. This occurs via a number of
pathways: first, a decrease in GFR prolongs the circulating half
life of heme proteins. Since heme endocytosis is a saturable
process, most of the filtered load is rapidly excreted. However, if
the period of heme proteinemia is prolonged due to a decrease in
GFR, more of the total filtered load can undergo reabsorption,
thereby exacerbating the extent of proximal tubular heme loading,
and hence, cell damage. Second, volume depletion, and hence
increased Na and fluid reabsorption, increase intraluminal myo-
globin concentrations, favoring cast formation and tubular ob-
struction; and third, tubular obstruction causes profound luminal
stasis, allowing more time for proximal tubular heme reabsorp-
tion, as discussed below [83]. These considerations merely under-
score that renal vasoconstriction can adversely impact the expres-
sion of myohemoglobinuric injury via divergent, but interrelated
pathways (Fig. 1).
Heme protein cast formation
The presence of large numbers of distal nephron heme pigment
casts have been noted in virtually every study of myohemoglobin-
uric ARF (see Fig. 2). Since some studies have also revealed
associated tubular dilatation [84—86], it has been widely hypoth-
esized that these casts induce tubular obstruction, thereby con-
tributing to the pathogenesis of the renal failure. Despite this
assumption, consistent micropuncture data to support this view
have been lacking. For example, Oken, Arce and Wilson reported
low, rather than high intratubular pressures in rat kidneys four
hours following glycerol-induced myohemoglobinuria [87]. The
tubules appeared collapsed, rather than dilated, and the casts
could be readily expelled by intraluminal fluid infusion under
normal pressures. These observations led these workers to con-
clude that the casts were a reflection of the filtration failure (that
is, no washout), rather than a cause of it. They also could not
demonstrate substantial tubular backleak, and hence it was con-
cluded that the ARF had a predominant hemodynamic basis. In a
study by Riuz-Guinazu, Coelho and Paz, assessments of tubular
pressures were made from 0 to 96 hours following the induction of
heme protein ARF, created by methemoglobin infusion [88]. Two
populations of tubules were noted. Some were dilated and had
normal—to—high intraluminal pressures. This population was pre-
dominantly (but not exclusively) found during the first few hours
of injury. The second nephron population had collapsed tubules,
and was typically observed during the maintenance phase of the
ARF. Very similar results to these were obtained by Jaenike, who
also used a methemoglobin infusion ARF model [89]. On the
basis of these studies, it has been suggested that intratubular
obstruction may not be a critical factor underlying heme protein-
induced filtration failure. However, it should be noted that
concomitant reductions in cardiac output and attendant renal
vasoconstriction would be expected to lower glomerular capillary
pressure. Hence, even "normal" intratubular pressures could be
abnormally high in this setting and therefore, contributed to a
decreased GFR. Furthermore, no compelling alternative explana-
tion for persisting filtration failure beyond the period of renal
vasoconstriction exists. Thus, the nephronal determinants of the
ARF, in general, and the precise role of cast formation, in
particular, remain to be defined.
Although one typically views cast formation as being important
to the pathogenesis of ARF because of its direct effects on
glomerular filtration, we have previously suggested that in the case
of heme protein nephrotoxicity, it may also play a critical role in
the induction of tubular necrosis. As alluded to above, we have
noted that the degree of proximal tubular heme uptake is
dramatically increased in the presence of even short-lived urinary
tract obstruction. For example, if heme proteins are infused into
rats with acute ureteral ligation, giant heme laden endolysosomes
form in proximal tubular segments [83]. Similarly, if cast forma-
tion is facilitated by infusing heme proteins into aciduric rats (see
below), proximal tubular heme endocytosis is, once again, greatly
enhanced [83]. Undoubtedly, this reflects the fact that an obstruct-
ing lesion induces luminal stasis, thereby providing an extended
t'_ -,
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Fig. 2. Characteristic mophologic changes of heme protein nephrotoxicity Oat kidney 8 hr following heme protein infusion [83]. Distal nephron heme casts
are seen (left), and giant heme-fllled endolysosomes are observed in occasional proximal tubular cells (middle). Many of the proximal tubular cells show
early signs of necrosis, leading to detachment from the basement membrane. Modest tubular dilatation is also observed (right center), suggesting that
a component of tubular obstruction exists. (Hematoxylin and eosin stain; perfusion fixed tissue).
period for proximal tubule endocytic transport. Since heme
protein cytotoxicity is clearly dose dependent, even transient cast
formation could have a profound impact on the evolution of ARF
by favoring toxin uptake and, therefore, the development of
tubular necrosis. As demonstrated by the above described mi-
cropuncture experiments, heme cast-induced tubular obstruction
appears to be more prominent during the initiation phase, rather
than the maintenance phase, of myohemoglobinuric ARF. Since
this early period corresponds with the stage of heme filtration and
thus heme endocytosis, even transient tubular obstruction at this
time could have a pronounced and prolonged impact on the
severity of the ARF.
The mechanism by which heme protein cast formation occurs
has been rather well characterized and is largely determined by
two factors: (1) the heme protein concentration in the distal
nephron; and (2) the characteristics of the urine in which it
resides. Since the degree to which heme proteins precipitate from
solution is, in part, concentration dependent, the amount of the
filtered load (determined in large part by the extent of muscle
injury), and the more that load is concentrated along the nephron,
the more likely it is that cast formation will result. Since volume
depletion and renal vasoconstriction enhance filtrate reabsorp-
tion, they can increase intraluminal heme concentrations, facili-
tating cast development. The second critical factor is urinary pH.
For example, if myoglobin is added to normal human urine at a
pH of 8.5, a solubility of  50 mg/ml can be achieved (exceeding
that which is typically found during experimental myohemoglo-
binuria [90]). However, as urinary pH is progressively lowered to
5.0 by HC1 addition, a progressive loss of myoglobin solubility
results, with 98% precipitating by the end of the titration [90]. An
in vivo correlate of this observation is that renal myoglobin
retention progressively increases with progressive reductions in
urine pH. For example, we previously observed that when urinary
pH was maintained at 8.0, 78% of an exogenous myoglobin load
was excreted. Conversely, under aciduric conditions, only 32% of
the myoglobin was eliminated [90]. This relationship undoubtedly
explains the long-standing experimental observation that aciduria
is an important determinant of heme protein-induced ARF. What
is less well appreciated, however, is that this pH effect is largely
Tamm Horsfall protein (THP) dependent. For example, if myo-
globin is added to 0.45% NaCI instead of urine, only 10%, not
98%, precipitates at a 5.0 pH [90]. A characteristic of THP is its
propensity to aggregate with other proteins under aciduric condi-
tions, forming casts [91, 92]. Undoubtedly, this is the principal
reason why urine facilitates heme protein precipitation under
conditions of a reduced pH. That THP is synthesized in the distal
nephron [93, 94], and that this is the predominant site at which
heme casts reside, further points to its central role to intraluminal
heme trapping. Ultimately, cast formation results not just from
heme proteins, but also from the evolving heme-induced proximal
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tubular necrosis. The underlying mechanisms for the latter are
discussed below.
Mechanisms of heme mediated proximal tubular cytotoxicity
In addition to cast formation, the second typical morphologic
feature of heme protein-induced ARF is proximal tubular necro-
sis (Fig. 2). That this lesion ultimately contributes to filtration
failure is indirectly supported by the fact that mitigating its
expression via pharmacologic interventions attenuates the severity
of ARF. Once proximal tubular injury is initiated, a host of
cellular degradative reactions and maladaptive responses (for
example, loss of membrane polarity, altered cell-cell interactions)
are undoubtedly called into play and ultimately contribute to
lethal cell injury. The nature of these interactive injury pathways
has been the subject of several recent excellent reviews [94—981.
Therefore, the present discussion will stress two factors which are
currently believed to play critical roles in the initiation of this
injury cascade: ischemic damage and oxidant tissue stress.
Ischemic tubular injury and A TP depletion
It has been recognized for at least 50 years that heme protein
nephrotoxicity and ischemic renal damage are inextricably linked
[99—101]. As previously detailed, this is probably mediated in part
by the ability of heme proteins to intensify renal vasoconstriction,
thereby converting an episode of renal hypoperfusion into a
severe ischemic insult [79]. Therefore, it may well be that myohe-
moglobinuric ARF is, in large part, ischemia induced. This
possibility is further supported by work from Trifillis, Kahng and
Trump in which substantial decrements in renal cortical ATP
content were noted early in the course of glycerol-induced ARF
[102].
However, it is also highly likely that an adverse heme protein-
ischemic interaction exists directly at the proximal tubular cell
level (that is, independent of hemodynamic influences). For
example, if an ordinarily non toxic dose of hemoglobin or
myoglobin is infused into a rat prior to the induction of a fixed
ischemic renal insult (renal artery occlusion; RAO), a marked
potentiation of ischemic tubular necrosis and filtration failure
result [99—101, 103]. In one of these studies, no detectable change
in renal perfusion was noted either before or after RAO [103],
strongly suggesting that the ischemic damage was potentiated
directly at the proximal tubular cell level. This conclusion was
further supported by the fact that this adverse heme effect was
expressed without any change in renal cortical/outer medullary
ATP content [103]. Hence, heme infusion seemingly worsened the
expression of the ischemic damage, rather than the severity of the
ischemic insult per se.
Since it has long been assumed that porphyrin iron is the
specific mediator of heme protein cytotoxicity [1041, we evaluated
whether this was the specific determinant of the above "ischemia-
potentiating" effect. If so, this would provide specific clues into
potential mechanisms. Towards this end, rats were infused with 25
mg of either myoglobin or non-iron-containing low molecular
weight proteins (anionic or cationic lysozyme, rihonuclease) [103].
Each rat was then subjected to a 25-minute ischemic insult (renal
artery occlusion). Surprisingly, each of these readily filtered low
molecular weight proteins markedly and equally potentiated the
severity of the superimposed ischemic insult. This was despite the
fact that none of the proteins in the dose employed exerted an
independent toxic effect. In contrast, albumin infusion (which
undergoes minimal filtration) had no discernible impact. Next, it
was demonstrated that cytochrome C, a readily filtered but
relatively poorly reabsorbed heme protein, did not exacerbate
superimposed ischemic damage. Thus, these experiments indi-
cated that endocytic protein reabsorption (or some secondary
consequence of it), and not cell iron loading per Se, is in large part
responsible for heme's ability to potentiate ischemic damage. The
low molecular weight protein infusions caused an early increase in
ischemia-triggered brush border membrane blebbing [103]. We
speculated that the protein endocytic reabsorptive process, or the
resulting plasma membrane lipid trafficking/"remodeling" [105],
may directly sensitize the plasma membrane to ischemia-triggered
attack [103].
To further explore this possibility, we have recently conducted
a series of experiments using a newly devised in vitro model of
heme protein cytotoxicity [106]. To induce a clinically relevant
form of proximal tubular heme protein exposure, rats or mice
were injected with glycerol. After allowing a two to four hour
period for heme protein endocytic reabsorption, the kidneys were
removed and proximal tubular segments (PTS) were isolated.
During subsequent in vitro incubations, these tubules typically
express progressive heme-induced cytotoxicity [106]. Since phos-
pholipase A2 is probably the critical determinant of ischemia-
triggered lethal membrane injury [95, 96], we then used this in
vitro model to assess whether heme endocytic transport/mem-
brane remodeling does, in fact, increase the plasma membrane's
susceptibility to PLA2 attack. To this end, control and heme
loaded PTS were incubated with exogenous PLA2 [107]. Over the
next hour, lethal cell injury and PLA2-induced deacylation were
assessed by lactate dehydrogenase release and arachidonic acid
release, respectively. Whereas PLA2 addition to normal PTS
induced no cell death and minimal deacylation, synergistic dam-
age occurred in the heme-loaded PTS, as assessed by both injury
parameters [107; unpublished data]. These data strongly sup-
ported the hypothesis that heme endocytosis directly sensitizes the
plasma membrane to PLA2 attack. In contrast, when PLA2 was
added to PTS which were damaged by hypoxia, a decrease rather
than an increase in cell death resulted [107, 108]. Thus, PLA2's
ability to exacerbate injury in the heme loaded tubules was not
merely due to a non-specific 'injury potentiating' effect. The
underlying mechanisms for these phenomena remain subjects of
ongoing investigation.
Another pathway by which heme proteins can contribute to
ischemic tubular damage is via an apparent adverse effect on
cellular energetics, independent of their negative impact on renal
perfusion. The following experiment provides support for this
concept. When normal rats were subjected to an intravenous
myoglobin infusion, an approximate 25% reduction in renal
cortical ATP concentrations developed without any discernible
change in renal hemodynamics [80]. This result could not be
reproduced by infusing a non-iron containing low molecular
weight protein (ribonuclease), suggesting an iron dependent
reaction. This conclusion was further supported by the fact that
when myoglobin was infused in the presence of an iron chelator
(deferoxamine; or DFO), no diminution in ATP resulted. In
summary, these considerations underscore that multiple and
potentially overlapping mechanisms for the heme protein-induced
exacerbation of ischemic renal injury exist: (i) heme proteins can
intensify renal vasoconstriction in the setting of volume depletion;
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(ii) they can adversely affect ATP availability via a non hemody-
namic, iron dependent mechanism; and (iii) heme protein endo-
cytic reabsorption can directly sensitize tubular cells to the
adverse consequences of superimposed ischemia-triggered injury
pathways (such as PLA2 attack). Given these multiple adverse
interactions, it is not surprising that renal ischemia and heme
protein nephrotoxicity have been inextricably linked in the liter-
ature.
Heme iron-induced oxidant stress
In 1969, Bunn and Jandi injected haptoglobin deficient animals
with tracer amounts of 59Fe labeled hemoglobin to determine its
metabolic handling by the kidney. They noted that the hemoglo-
bin rapidly dissociated within the circulation into af3 dimers
(thereby halving its size, permitting rapid filtration) and this was
followed by proximal tubule heme endocytic reabsorption [109].
Once within proximal tubular cells, the porphyrin ring was rapidly
catabolized, releasing its iron content. The latter was then trans-
ferred to ferritin. Subsequently, the intratubular 59Fe disappeared
over several weeks. In contrast, if large amounts of hemoglobin
were administered, the tubular reabsorptive capacity was ex-
ceeded, producing marked hemoglobinuria [110] and intraluminal
free iron release [110, 111]. These same events undoubtedly occur
during myoglobinemia/uria, with the exception that myoglobin's
small size (—17 kD) permits ready filtration without in vivo
modification. The importance of these events to the pathogenesis
of heme-induced proximal tubular injury is underscored by our
current belief that heme protein toxicity is free iron induced. The
evidence underlying this conclusion is discussed below.
A large body of in vivo and in vitro evidence support the concept
that oxygen and non oxygen-based free radicals are critical
mediators of extrarenal and renal injury [112—i 14]. Since iron is a
transition metal which readily accepts and donates electrons, it
greatly facilitates free radical production and may itself become a
free radical [115—119]. Iron chelators, such as, DFO and 2,3-
dihydroxybenzoic acid, have been shown to protect against seem-
ingly diverse models of tissue injury. Iron-induced oxidant stress
has become a generally accepted mediator of tissue damage
[120—123]. Given this background information, and with Bunn's
finding of intratubular cell iron release during hemoglobinuria, it
seemed highly plausible that "catalytic" iron (that is, capable of
promoting free radical reactions) could play a critical role in
heme-induced nephrotoxicity. Two seminal studies substantiating
this hypothesis were published simultaneously in 1988. Paller
noted that DFO therapy mitigated three models of myohemoglo-
binuric renal injury: i.v. hemoglobin-induced nephrotoxicity, glyc-
erol-induced ARF, and a combined renal ischemic/hemoglobin-
uric insult [124]. In the second study, Shah and Walker
demonstrated that DFO and hydroxyl radical scavengers each
protected against the glycerol ARF model [125]. Both of these
studies reported a heme-induced increase in renal lipid peroxida-
tion, as assessed by malondialdehyde (MDA) generation. This
observation, and that hydroxyl radical scavengers completely
prevented the MDA increment [125], strongly supported the
concept that intrarenal heme iron accumulation induces hydroxyl
radical formation and thus, oxidant renal damage.
In subsequent studies, Shah et al have provided further com-
pelling evidence for the role of reactive oxygen species in the
propagation of heme protein nephrotoxicity. Using the aminotria-
zole method, they first demonstrated increased H2O2 production
in rat kidneys following myohemoglobinuria [126]. Since this is a
"substrate" for hydroxyl radical formation via the iron catalyzed
Fenton/Haber-Weiss reactions [115], this finding provided addi-
tional support for the authors' previously advanced hypothesis
that hydroxyl radical is a mediator of heme-induced renal tubular
damage. Next, they demonstrated that manipulations in the rat's
renal glutathione status altered the expression of heme-induced
tissue injury [127]. When rats were supplemented with glutathi-
one, they were partially protected against glycerol-induced ARF.
Conversely, when glutathione was depleted with L-buthionine-
(S,R) sulfoximine, a worsening of ARF resulted. Since glutathione
is a potent antioxidant, particularly in terms of eliminating H202,
these studies firmly established the role of H2O2, and possibly its
iron-catalyzed byproducts, in the induction of myohemoglobinuric
ARF. Since H202 can cause iron release from intracellular
sequestration sites (such as the cytochromes [111]), it may further
promote oxidant stress by increasing the intracellular free, or
"catalytic," iron burden.
In a series of elegant experiments, Nath et a! substantially
advanced our understanding of iron-induced oxidant stress in
myohemoglobinuric renal injury by detailing the critical roles
played by heme oxygenase and ferritin [128]. Since heme oxyge-
riase (HO) degrades the porphyrin ring, it causes free iron release
which then up-regulates intracellular ferritin expression, a key
defense against iron-induced tissue damage. To demonstrate the
involvement of these proteins in heme-induced ARF, HO inhibi-
tion was induced by Sn protoporphyrin administration: decreased
ferritin expression and an exacerbation of the glycerol ARF model
resulted [128]. Conversely, when ferritin expression was up-
regulated by injecting rats with a subtoxic dose of hemoglobin 24
hours prior to glycerol injection, marked cytoprotection resulted
[128]. We have recently found that acute HO inhibition (that is,
without allowing time for increased ferritin expression) acutely
protects against in vitro myohemoglobinuric proximal tubular
cytotoxicity, undoubtedly because it inhibits heme iron release
[106]. Thus, HO inhibition can have seemingly 'paradoxical'
effects: on the one hand, it decreases ferritin expression, predis-
posing to iron toxicity; on the other hand, it can protect against
heme toxicity by preventing heme iron liberation. Finally, we have
demonstrated that DFO completely blocks myohemoglobinuric
injury in our new in vitro model system [106]. Thus, when each of
these studies are viewed together, they provide overwhelming
evidence that iron is the key determinant of heme protein's
cytotoxic effect.
Despite the above, at least three critical questions regarding the
nature of heme iron-induced proximal tubular injury remain
unresolved: first, which free radical(s) initiate and propagate the
injury? Second, what are the site(s) and pathways of iron-based
free radical production? Third, what are the critical biochemical
targets, injury to which culminate in cell death? In regards to the
first issue, Walker and Shah have provided compelling evidence
that H202 and hydroxyl radical are important mediators of in vivo
myohemoglobinuric ARF [126, 127]. However, we have been
unable to demonstrate that either catalase or hydroxyl radical
scavengers mitigate the in vitro expression of that injury directly at
the proximal tubular cell injury [106]. This raises the possibility
that these antioxidants might exert some of their protection via
vascular or intraluminal effects. Of further note is that DFO's
cytoprotective action in vitro has not correlated with any apparent
decrease in hydroxyl radical production [106, 111, 129]. Thus, the
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specific free radical(s) which propagate heme iron-induced injury
remain in doubt [106, 118, 130, 131].
Regarding the second issue, a recent study from our laboratory
provides evidence for the mitochondrion as a critical site of
heme-induced free radical formation [132]. When heme laden
proximal tubular segments were exposed to mitochondrial respi-
ratory chain inhibitors, profound alterations in the expression
oxidant cell injury (lipid peroxidation) resulted: blockade at site 2
(with antimycin A) or site 3 (with cyanide or hypoxia) completely
prevented heme-induced MDA generation. Conversely, site 1
blockade dramatically increased oxidative damage. In contrast,
these agents had virtually no effect on lipid peroxidation in normal
tubules. Therefore, these results strongly point to the mitochon-
dna! respiratory chain, in general, and its terminal portion, in
particular, as a critical site of heme-induced free radical forma-
tion. Since free radicals tend to induce injury at the site of their
formation, it would be predicted that mitochondnial damage
would result. While a defect in cellular energetics was docu-
mented in the above study (a modest decrement in ATP/ADP
ratios), total cellular ATP was reasonably well preserved. To
summarize, these experiments suggest that while the mitochon-
dna might fuel lipid peroxidation, they are probably not the
critical subcellular target of iron dependent free radical attack.
Finally, the critical molecular targets of heme iron-induced
oxidant stress remain largely unknown. While evidence has been
presented that lipid, DNA, and protein oxidation may all be
involved [106, 111, 124, 125, 133], linking oxidation of these
cellular constituents to lethal cell injury has been exceedingly
difficult to establish. As one example, although most studies have
documented that lipid peroxidation accompanies heme protein
nephrotoxicity, in vitro studies have not demonstrated that these
two processes are directly related. For example, although addition
of glutathione to heme loaded proximal tubules can protect them
from lethal injury, it can also paradoxically increase lipid peroxi-
dation [106]. Presumably this is because thiols can undergo
autoxidation reactions, H202 production being a result [20, 134].
Conversely, addition of either ferrous and ferric salts to normal
tubules induces massive and equal degrees of lipid peroxidation;
however, only the former acutely induces cell death [129]. Given
these complexities and the seemingly endless number of potential
targets, it is unlikely that the specific, critical molecular lesion(s)
underlying iron-induced cytotoxicity will soon become apparent.
Additional potential mediators of myohemoglobinuric ARF
For the sake of completeness, it should be recalled that
rhabdomyolysis and hemolysis release more than just heme
proteins into the circulation, raising the possibility that other
cellular constituents might contribute to acute renal injury. As one
example, clinically relevant degrees of hyperphosphatemia can
markedly potentiate both experimental ischemic and nephrotoxic
renal damage [135]. Hyperuricemia, another byproduct of exces-
sive tissue catabolism, can contribute to cast formation and
intratubular obstruction. Furthermore, since it is an organic
anion, and since organic anion transport can potentiate experi-
mental ischemic tubular injury [136], hyperuricemia could also
impact on heme-protein associated ischemic tubular damage.
Rhabdomyolysis can also trigger disseminated intravascular coag-
ulation via tissue thromboplastin release, potentially causing
intrarenal microthrombus formation. Thus, while heme protein-
uria and renal ischemia may be the best documented mediators of
rhabdomyolysis and hemolysis-associated renal injury, it is prob-
ably overly simplistic to assume that other tissue derived factors
are not involved [137].
Prevention and therapy of heme pigment nephropathy
Seventy-five years of investigation into the pathogenesis of
heme protein nephrotoxicity has led to rational strategies for
preventing this form of ARF. The cornerstones of that therapy are
as follows: (1) correction of hypovolemia and any attendant renal
ischemia; (2) enhance the clearance of heme proteins from the
circulation and the kidney; and (3) mitigate the direct adverse
consequences of heme proteins on the proximal tubular epithe-
hum.
Volume replacement therapy
Since intravascular volume status has such a profound impact
on the development of experimental heme protein-induced ARF,
vigorous intravenous fluid therapy, oftentimes administered with
mannitol and NaHCO3 (see below), is a mainstay in the early
management of clinical rhabdomyolysis or severe intravascular
hemolysis. Although no prospective clinical trials have proven
their efficacy, retrospective analyses by Better and co-workers
provide overwhelming support for their use [14, 58, 59]. These
investigators compared the clinical outcomes of two groups of
patients who developed crush syndrome during building collapses.
In the first group of 7 patients seen in 1979, volume expansion was
not instituted for up to at least six hours following patient
extrication from the injury site, and in each case, ARF developed.
In contrast, 7 patients who suffered similarly severe crush injuries
in 1982 received i.v. saline therapy starting at, or even before, their
extrication, and none developed ARF. An eighth patient in this
latter series served as an "unintentional control" since on site
fluid resuscitation was inadvertently omitted and ARF developed.
Eneas, Schoenfeld and Humphnies suggested that i.v. volume
expansion may also be efficacious for non-traumatic rhabdomy-
olysis [138]. Thus, compelling clinical and experimental observa-
tions strongly support a role for aggressive, and most importantly,
early fluid replacement (before substantial cast formation, heme
endocytic uptake, and tubular necrosis occur). The critical ques-
tions are how much and what types of fluids should be adminis-
tered? Based on Better's extensive personal experience with the
crush syndrome, he recommends 1.5 liters/hr of normal saline as
soon as a trapped limb is freed [16]. Once monitoring is possible,
sufficient volume is administered to normalize systemic hemody-
namics. Assuming that the patient can respond with an appropri-
ate urine output, he then recommends —12 liters per day of a
mannitol/alkahine diuresis [16]. In contrast, considerably smaller
volumes were used by Eneas et al in managing non-traumatic
rhabdomyolysis [138]. Obviously, no firm rules exist, other than to
"individualize" therapy.
Enhancing heme protein elimination
Volume expansion is critical to achieving this goal since im-
proving GFR (reversing pre-renal azotemia, preventing ischemic
tubular injury), inducing a diuresis, and diluting out intralumina!
heme proteins lessen the risk of cast formation. The latter result
may also lessen proximal tubular heme uptake, as previously
discussed. Based on the pronounced protective effects of urinary
alkalinization on experimental models of heme protein nephro-
toxicity, systemic NaHCO5 therapy is usually recommended, with
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a goal of achieving a urine pH of > 6.5 [16, 138]. In our
experience, the dosing requirements to achieve this goal vary
considerably amongst patients. A particularly compelling case for
systemic alkalinization can be made if severe myolysis, acidosis,
and early renal dysfunction have produced severe hyperkalemia.
However, it is worth noting that alkalemia may also predispose to
hypocalcemia, which may already exist in patients with severe
rhabdomyolysis due in part to hyperphosphatemia and skeletal
muscle Ca2 deposition [139]. While alkali-induced hypocalcemia
may represent a theoretical risk, its occurrence could have dire
consequences in crush syndrome patients. For example, were
seizures to develop, further muscle injury and complications of
pre-existent fractures could result. From a pathophysiologic
standpoint, it should be noted that some of bicarbonate's protec-
tive effect stems from its serving as a non-reabsorbed solute which
promotes a diuresis [90]. Whether alkalinization is useful once a
brisk diuresis has been achieved with saline or diuretics (see
below) remains unknown.
Mannitol has been repeatedly shown to protect against exper-
imental myohemoglobinuric ARF, and hence, it is often added to
saline/bicarbonate infusions. Multiple potential pathways for its
protective actions exist: first, as a proximal acting diuretic, it is
highly effective in facilitating heme protein/heme iron excretion
[111]. Thus, a lessening of heme endocytosis and cast formation
may result. Second, since it is a potent renal vasodilator, it may
improve renal perfusion, possibly mitigating renal ischemic dam-
age [140]; and third, since mannitol is a hydroxyl radical scavenger,
it can theoretically decrease heme iron-induced oxidant stress. To
test the relative importance of these actions, our laboratory
studied the impact of mannitol on the glycerol model of ARF
[141]. In that study, mannitol's protective action could be com-
pletely ascribed to a solute diuresis and increased heme excretion.
This conclusion was based on the fact that a comparable solute
diuresis induced by Na2SO4 infusion induced comparable protec-
tion. Furthermore, if the amount of heme protein which was
excreted during the mannitol diuresis was returned to the rat by
intravenous infusion, protection no longer resulted. Since manni-
tol is largely an impermeant solute, it is unlikely to effectively
scavenge hydroxyl radical at an intracellular location. This con-
sideration, plus the fact that Na2SO4 (which does not scavenge
hydroxyl radical) conferred equal protection to mannitol, further
suggests that mannitol's antioxidant property does not substan-
tially contribute to its beneficial effect. Interestingly, although
mannitol is a potent vasodilator, it may actually worsen, rather
than improve, cellular energetics during the induction of ARF.
For example, if administered immediately after renal ischemia
[140] or during the early phase of glycerol-induced ARF [141],
renal cortical ATP levels may abruptly decline. Although seem-
ingly paradoxical, mannitol increases the metabolic cost (ATP
consumption) of Na reclamation [142]. While under normal
circumstances this has no effect on ATP concentrations, in the
presence of concomitant tubular damage, a worsening of cellular
energy depletion may result. Thus, improvements in renal perfu-
sion and in cellular energetics need not be synonymous. Given
these considerations, it is theoretically possible that furosemide
might be a preferable diuretic. However, this remains only a
theoretical possibility that remains to be tested. When mannitol is
employed, it is critical to monitor serum osmolality to avoid a
hyperosmolar state. This is particularly likely to occur in the
setting of a substantially reduced GFR, limiting its filtration.
In the case of crush injuries, care of the damaged tissue may
limit myoglobin release into the circulation, and hence decrease
the renal burden. Better and Stein have suggested that mannitol
may lower muscular intracompartmental pressures in experimen-
tal crush syndrome [16]. If a limitation of muscle necrosis were to
result, this would be another potential benefit of mannitol admin-
istration. Surgical exploration, decompression, and fasciotomy
have also been employed in an attempt to achieve this goal.
However, Better and Stein have urged conservative management
because of the risk of infections and possible limb loss [16]. In
their view, surgery should only be undertaken when the limb is
threatened by high intracompartmental pressures (>40 mm Hg,
or < 30 mm Hg below diastolic pressure), confirmed by direct
manometry. Finally, it is theoretically possible that extracorporeal
elimination of circulating heme proteins could limit the renal
heme burden. However, because of its size, myoglobin is poorly
removed by either peritoneal dialysis or high permeability hemo-
filters [143]. Furthermore, even in the presence of severe ARF,
circulating myoglobin levels fall exponentially with the cessation
of its muscular release, probably because of hepatic and splenic
uptake [143]. Thus, no compelling data indicating a role for
extracorporeal heme protein removal (such as, by plasmapheresis)
currently exists.
Limiting heme protein cytotoxicity
Each of the above interventions would be expected to limit
heme protein proximal tubular injury since decreased proximal
tubular heme endocytic transport should result. While the exper-
imental literature has suggested a number of highly promising
cytoprotective interventions, none have yet to undergo clinical
trials. In our view, the most promising are the iron chelators, such
as DFO, since they have been uniformly protective when used in
divergent models of myohemoglobinuric tubular injury [106, 111,
124, 125]. Based on compelling in vivo data, glutathione supple-
mentation also seems promising [127]. However, in vitro experi-
ments suggesting that glutathione can exert pro- as well as
anti-oxidant effects [106], and that Scaduto et al have found that
glutathione may worsen experimental ischemic ARF [144], cause
some reservation.
Future directions
Although an enormous amount of work has been directed at the
prevention and treatment of early rhabdomyolysis-induced ARF,
methods to enhance renal recovery in this syndrome have received
little attention. Interventions to limit ongoing muscle injury may
prove particularly rewarding since decreased renal heme exposure
would result. Given the impressive experimental results obtained
with growth factor therapy in diverse forms of toxic and ischemic
renal injury [145], this approach may also prove useful. The
impact of acute hemodialysis on the expression of heme protein
nephrotoxicity also needs to be assessed. In light of the prolonged
half life of intratubular cell iron [109], it seems possible that iron
overload could predispose the tubular cell to recurrent damage in
response to adverse dialytic events [146—148]. Finally, it must be
recognized that in many ways, rhabdomyolysis-induced ARF is a
societal and not just a medical disease. War, terrorism, trauma,
poor building design and construction, inadequate earthquake
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preparedness, and drug abuse remain leading causes of this
syndrome. Hence, elimination of this disease will require social as
well as medical interventions.
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